COVID 19- Biochemical and Other Mechanisms associated with Neuropathy and Stroke. : Biochemical and Other Mechanisms associated with Neuropathy and Stroke

Loung V  Umedani; Quratulain  Javaid

doi:10.37762/jgmds.11-2.583

Authors

Loung V Umedani Bahria University Health Sciences, Campus Karachi
Quratulain Javaid Bahria University Health Sciences, Campus Karachi

DOI:

https://doi.org/10.37762/jgmds.11-2.583

Keywords:

COVID-19, SARS-CoV-, Biochemical Mechanisms, Stroke, Neuropathy

Abstract

The Coronavirus (SARS-C0V-2) caused COVID 19 disease, commencing from China in December 2019 and soon in 2020 its neurological manifestations were noted. The viral spike (S) protein binding with host cell receptor angiotensin-converting enzyme 2 (ACE2) with assistance of membrane fusion protease (TMPRSS) caused viral entry in host cells. We searched 47 articles using PubMed from January 2021 to January 2023. The initial pooling of virus in nasal mucosa was followed by spread to respiratory and other tissues. This review highlights the neuropathy and stroke mechanisms. The role of receptors, enzymes, proteins and genes in neuropathological mechanisms are highlighted. Vascular endothelial effects, choroid plexus and Blood Brain Barrier disruptions were noted. The epigenetic neuropathological mechanisms need to be explored further to help in designing new therapeutic modalities. The post vaccination neurological manifestations as well as the post COVID effects both need further attention to promptly diagnose and start timely treatment.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Author Biographies

Loung V Umedani, Bahria University Health Sciences, Campus Karachi

Assistant Professor,
Department of Biochemistry,
Bahria University Health Sciences, Campus Karachi

Quratulain Javaid, Bahria University Health Sciences, Campus Karachi

Associate Professor,
Anatomy Department,
Bahria University Health Sciences, Campus Karachi

References

Drosten C, Günther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003;348(20):1967–1976

Li B, Si H-R, Zhu Y, et al. Discovery of bat coronaviruses through surveillance and probe capture-based next-generation sequencing. mSphere, 2020;5:1

Khaled Habas, Chioma Nganwuchu, Fanila Shahzad, Rajendran Gopalan, Mainul Haque, Sayeeda Rahman, Anwarul Azim Majumder & Talat Nasim. Resolution of coronavirus disease 2019 (COVID-19), Expert Review of Anti-infective Therapy, 2020;18(12):1201-1211

Kanberg N, Ashton NJ, Andersson LM, Yilmaz A, Lindh M, Nilsson S. Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19. Neurology. 2020;95(12):e1754–e1759

Gu J, Gong E, Zhang B, Zheng J, Gao Z, Zhong Y, et al. Multiple organ infection and the pathogenesis of SARS. J Exp Med 2005;202:415-424

Najafloo R, Majidi J, Asghari A, Aleemardani M, Kamrava SK, Simorgh S, Seifalian A, Bagher Z, Seifalian AM. Mechanism of Anosmia Caused by Symptoms of COVID-19 and Emerging Treatments. ACS Chem Neurosci. 2021 Oct 20;12(20):3795-3805

Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145–147

Chen R, Wang K, Yu J, Howard D, French L, Chen Z, et al. The spatial and cell-type distribution of SARS-CoV-2 receptor ACE2 in human and mouse brain. Front. Neurol. 2021;11:573095

Klein, Robyn S. Mechanisms of coronavirus infectious disease 2019-related neurologic diseases. Current Opinion in Neurology. 2022;35(3):392-398

Brola W, Wilski M. Neurological consequences of COVID-19. Pharmacol Rep. 2022;30:1–15

Marshall M. COVID and the brain: researchers zero in on how damage occurs. Nature. 2021;595(7868):484‐485

Ribeiro DE, Oliveira‐Giacomelli Á, Glaser T, et al. Hyperactivation of P2X7 receptors as a culprit of COVID‐19 neuropathology. Mol Psychiatry. 2021;26(4):1044‐1059

Butowt R, von Bartheld CS. Anosmia in COVID-19: Underlying Mechanisms and Assessment of an Olfactory Route to Brain Infection. Neuroscientist. 2021;27(6):582-603

Cantuti-Castelvetri L, Ojha R, Pedro LD, et al. Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. Science 2020 Nov 13;(370):856-860

Prajapat M, Sarma P, Shekhar N, Avti P, Sinha S, Kaur H, Kumar S, Bhattacharyya A, Kumar H, Bansal S, Medhi B. Drug targets for corona virus: A systematic review. Indian J Pharmacol. 2020 Jan-Feb;52(1):56-65

Shi CS, Nabar NR, Huang NN, Kehrl JH. SARS-coronavirus open reading frame-8b triggers intracellular stress pathways and activates NLRP3 inflammasomes. Cell Death Discov. 2019;5:101

Schurink B, Roos E, Radonic T, Barbe E, Bouman CSC, de Boer HH, et al. Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study. Lancet Microbe. (2020);1:e290–9

Zhang L, Zhou L, Bao L, Liu J, Zhu, H, Lv Q, Liu R, Chen W, Tong W, Wei Q, et al. SARS-CoV-2 crosses the blood–brain barrier accompanied with basement membrane disruption without tight junctions alteration. Signal Transduct. Target. Ther. 2021 Sep 6;6(1):337

Afzali B, Noris M, Lambrecht BN, Kemper C. The state of complement in COVID-19. Nat Rev Immunol. 2022 Feb;22(2):77-8

Billoir P, Alexandre K, Duflot T, Roger M, Miranda S, Goria O, et al. Investigation of Coagulation Biomarkers to Assess Clinical Deterioration in SARS-CoV-2 Infection. Front Med (2021);8:670694

Uginet M, Breville G, Hofmeister J, Machi P, Lalive PH, Rosi A, et al. Cerebrovascular Complications and Vessel Wall Imaging in COVID-19 Encephalopathy-A Pilot Study. Clin Neuroradiol. 2022 Mar;32(1):287-293

Carod-Artal FJ. Neurological complications of coronavirus and COVID-19. Rev Neurol. 2020 May 1;70(9):311-322

Poyiadji N, Shahin G, Noujaim D, et al. COVID-19-associated acute hemorrhagic necrotizing encephalopathy: imaging features. Radiology. 2020;296(2):E119–E120

Esenwa C, Cheng NT, Luna J, Willey J, Boehme AK, Kirchoff-Torres K, et al. Biomarkers of Coagulation and Inflammation in COVID-19-Associated Ischemic Stroke. Stroke. 2021;52(11):e706-e709

Dharmalingam P, Talakatta G, Mitra J, Wang H, Derry PJ, Nilewski LG, et al. Pervasive Genomic Damage in Experimental Intracerebral Hemorrhage: Therapeutic Potential of a Mechanistic-Based Carbon Nanoparticle. ACS Nano. 2020 Mar 24;14(3):2827-2846

Yang AC, Kern F, Losada PM, Agam MR, Maat CA, Schmartz GP, et al. Dysregulation of brain and choroid plexus cell types in severe COVID-19. Nature. 2021;595(7868):565–571

Sen R, Garbati M, Bryant K, Lu Y. Epigenetic mechanisms influencing COVID-19. Genome. 2021 Apr;64(4):372-385

Urbanus RT, Pennings MT, Derksen RH, de Groot PG. Platelet activation by dimeric beta2-glycoprotein I requires signaling via both glycoprotein Ib alpha and apolipoprotein E receptor 2’. J Thromb Haemost. 2008 Aug;6(8):1405-12

Reynolds JL, Mahajan SD. SARS-COV2 alters blood brain barrier integrity contributing to neuro-inflammation. J. Neuroimmune Pharmacol. 2021;16(1):4-6

Valderrama EV, Humbert K, Lord A, Frontera J, Yaghi S. Severe acute respiratory syndrome coronavirus 2 infection and ischemic stroke. Stroke. 2020 Jul;51(7):e124-e127

Du F, Liu B, Zhang S. COVID-19: the role of excessive cytokine release and potential ACE2 down-regulation in promoting hypercoagulable state associated with severe illness. J Thromb Thrombolysis. 2021 Feb;51(2):313-329

Wenzel J, Lampe J, Müller-Fielitz H, Schuster R, Zille M, Müller K, Krohn M, Körbelin J, Zhang L, Özorhan Ü, et al. The SARS-CoV-2 main protease Mpro causes microvascular brain pathology by cleaving NEMO in brain endothelial cells. Nat. Neurosci. 2021;24,1522–1533

Mitra J, Kodavati M, Provasek VE, Rao KS, Mitra S, Hamilton DJ, Horner PJ, Vahidy FS, Britz GW, Kent TA, Hegde ML. SARS-CoV-2 and the central nervous system: Emerging insights into hemorrhage-associated neurological consequences and therapeutic considerations. Ageing Res Rev. 2022;80:101687

Kopp R, Krautloher A, Ramírez‐Fernández A, Nicke A. P2X7 interactions and signaling ‐ making head or tail of it. Front Mol Neurosci. 2019;12:183

Paniri A, Akhavan-Niaki H. Emerging role of IL-6 and NLRP3 inflammasome as potential therapeutic targets to combat COVID-19: Role of lncRNAs in cytokine storm modulation. Life Sci. 2020 Sep 15;257:118114

Tavčar P, Potokar M, Kolenc M, Korva M, Avšič-Županc T, Zorec R, Jorgačevski J. Neurotropic Viruses, Astrocytes, and COVID-19. Front. Cell. Neurosci. 2021;15:662578

Welcome MO, Mastorakis NE. Neuropathophysiology of coronavirus disease 2019: neuroinflammation and blood brain barrier disruption are critical pathophysiological processes that contribute to the clinical symptoms of SARS-CoV-2 infection. Inflammopharmacology. 2021 Aug;29(4):939-963

Sun B, Tang N, Peluso MJ, Iyer NS, Torres L, Donatelli JL, et al. Characterization and Biomarker Analyses of Post-COVID-19 Complications and Neurological Manifestations. Cells. 2021 Feb 13;10(2):386

Taheri M, Rad LM, Hussen BM, Nicknafs F, Sayad A, Ghafouri-Fard S. Evaluation of expression of VDR-associated lncRNAs in COVID-19 patients. BMC Infect Dis. 2021;21:588.

Choe K, Park HY, Ikram M, Lee HJ, Park TJ, Ullah R, Kim MO. Systematic Review of the Common Pathophysiological Mechanisms in COVID-19 and Neurodegeneration: The Role of Bioactive Compounds and Natural Antioxidants. Cells. 2022;11(8):1298

Chernyak BV, Popova EN, Prikhodko AS, Grebenchikov OA, Zinovkina LA, Zinovkin RA. COVID-19 and oxidative stress. Biochem. 2020;85:1543–1553

Dash S, Dash C, Pandhare J. Therapeutic significance of microRNA-mediated regulation of PARP-1 in SARS-CoV-2 infection. Non-Coding RNA. 2021;7(4):60

Mahalaxmi I, Kaavya J, Mohana Devi S, Balachandar V. COVID‐19 and olfactory dysfunction: a possible associative approach towards neurodegenerative diseases. J Cell Physiol. 2021; 236(2):763–70

Restivo DA, Centonze D, Alesina A, Marchese-Ragona R. Myasthenia gravis associated with SARS-CoV-2 infection. Ann Intern Med. 2020;173(12):1027–1028

Aladawi M, Elfil M, Abu-Esheh B, Abu Jazar D, Armouti A, Bayoumi A, Piccione E. Guillain Barre Syndrome as a Complication of COVID-19: A Systematic Review. Can J Neurol Sci. 2022;49(1):38-48

Ahmad SJ, Feigen CM, Vazquez JP, Kobets AJ, Altschul DJ. Neurological Sequelae of COVID-19. J Integr Neurosci. 2022;21(3):77

Oaklander AL, Mills AJ, Kelley M, Toran LS, Smith B, Dalakas MC, Nath A. Peripheral Neuropathy Evaluations of Patients with Prolonged Long COVID. Neurol Neuroimmunol Neuroinflamm. 2022;9(3):e1146

Benton DJ, Wrobel AG, Xu P, et al. Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion. Nature 2020; 588:327–330

Victor Altmayer, Jason Ziveri, Corinne Frère, Joe-Elie Salem, Nicolas Weiss, Albert Cao, et al. Endothelial cell biomarkers in critically ill COVID-19 patients with encephalitis Wiley Online Library Journal of Neurochemistry (JNC). 2022;161(6):492-505

Alirezaei Z, Pourhanifeh MH, Borran S, Nejati M, Mirzaei H, Hamblin MR. Neurofilament light chain as a biomarker, and correlation with magnetic resonance imaging in diagnosis of CNS-related disorders. Mol Neurobiol. 2020;57(1):469- 491

Sahin BE, Celikbilek A, Kocak Y, Saltoglu GT, Konar NM, Hizmali L. Plasma biomarkers of brain injury in COVID-19 patients with neurological symptoms. J Neurol Sci. 2022;439:120324

Ostuzzi G, Gastaldon C, Papola D, Fagiolini A, Dursun S, Taylor D, Correll CU, Barbui C. Pharmacological treatment of hyperactive delirium in people with COVID-19: rethinking conventional approaches. Therapeutic Advances in Psychopharmacology. 2020;10:2045125320942703

Dubovsky AN, Arvikar S, Stern TA, et al. The Neuropsychiatric Complications of Glucocorticoid Use: Steroid Psychosis Revisited. Psychosomatics. 2012;53(2):103–115

Pariante CM, Lightman SL. The HPA axis in major depression: classical theories and new developments. Trends Neurosci. 2008;31(9):464-468